Conclusion: SCG2 and CCL19 are potential novel biomarkers of Calcific aortic valve disease (CAVD) and may play important roles in the biological process of Calcific aortic valve disease (CAVD). This evidence concerns the gene SCG2 and congenital bilateral aplasia of vas deferens from CFTR mutation.